Background. K. pneumoniae is an important pathogen both outside and inside the hospital. The cells of the microorganism and bacteria under stress and damage begin to produce heat shock proteins that signal the defeat of their own cells. In addition, a large number of these proteins is produced by endothelial cells activated by cytokines. Cytokines provide well-coordinated cooperation in functions of immune, endocrine and nervous systems under normal conditions. Pro- and anti-inflammatory cytokines provide full and adequate formation of the inflammatory response in the body. The use of cytokines as pharmacological agents in the treatment of inflammatory diseases is considered to be perspective.
The aim of research was to determine the content of interleukins 17 and 18 in serum under experimental pyoinflammatory infection caused by K. pneumoniae with further explanation of their their in its pathogenesis.
Materials and methods. Experimental model of pyoinflammatory process adapted to K. pneumoniae was provided on mice, male of line C57BL/J6Sto in accordance to European Convention for the Protection of spinal animals used for experimental and other scientific purposes. For treating infected animals were used only amikacin and its combination with roncoleukin or glutaxim. Levels of interleukins were determined using ELISA kits,VECTOR-BEST,Russia. Statistical analysis of the results was provided with program for Exel PC and Biostat.
Results and discussion. Analysis of the results of the study revealed that in the group of infected animals, the level of IL-17 and IL-18 exceed index of intact animals indicating the active inflammation in experimental animals. Under influence of amikacin and amikacin with roncoleukin levels of IL-17 and IL-18 decreased, but amikacin with immunomodulator glutaxim led to lower levels of marked cytokines than in intact animals. It should be noted that the use of roncoleukin in the treatment does not promote normalization of IL-18, that’s why a recommend immunomodulator for the treatment is glutaxim. Obtained data have shown that the use of immunomodulators in the treatment of inflammatory processes caused by K. pneumoniae is necessary. Prospects for future research is to determine the relationship between intensity of cytokines levels and cellular immunity, which will develop criteria for predicting risk of chronic inflammation caused K. pneumoniae.